A new trading day began on Tuesday, with Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) stock price up 3.61% from the previous day of trading, before settling in for the closing price of $28.22. CRNX’s price has ranged from $24.10 to $62.53 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -12.11%. Meanwhile, its annual earnings per share averaged -20.31%. With a float of $86.72 million, this company’s outstanding shares have now reached $93.53 million.
Let’s determine the extent of company efficiency that accounts for 437 employees. In terms of profitability, gross margin is 0.92%, operating margin of -49569.74%, and the pretax margin is -43191.05%.
Crinetics Pharmaceuticals Inc (CRNX) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Crinetics Pharmaceuticals Inc is 7.43%, while institutional ownership is 104.48%. The most recent insider transaction that took place on Jun 12 ’25, was worth 3,141,877. In this transaction Chief Scientific Officer of this company sold 97,483 shares at a rate of $32.23, taking the stock ownership to the 99,713 shares. Before that another transaction happened on Jun 12 ’25, when Company’s Officer proposed sale 97,483 for $32.33, making the entire transaction worth $3,151,625.
Crinetics Pharmaceuticals Inc (CRNX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -20.31% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 3.37% during the next five years compared to -12.11% drop over the previous five years of trading.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Trading Performance Indicators
Here are Crinetics Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 22.53. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7608.90.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.82, a number that is poised to hit -1.08 in the next quarter and is forecasted to reach -4.60 in one year’s time.
Technical Analysis of Crinetics Pharmaceuticals Inc (CRNX)
Looking closely at Crinetics Pharmaceuticals Inc (NASDAQ: CRNX), its last 5-days average volume was 1.03 million, which is a jump from its year-to-date volume of 0.94 million. As of the previous 9 days, the stock’s Stochastic %D was 20.12%.
During the past 100 days, Crinetics Pharmaceuticals Inc’s (CRNX) raw stochastic average was set at 41.62%, which indicates a significant increase from 28.90% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.34 in the past 14 days, which was lower than the 1.48 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $30.71, while its 200-day Moving Average is $39.57.
